Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597393 | 0.87 | KIF11 (0.44) | KIF11TRPV1FABP7FABP5NPC1 | |
| SCHEMBL3607060 | 0.87 | KIF11 (0.41) | KIF11TRPV1FABP7FABP5NPC1 | |
| SCHEMBL3598229 | 0.83 | KIF11 (0.68) | KIF11TRPV1RAB9AGRM5 | |
| SCHEMBL396156 | 0.79 | DDX3X (0.59) | TRPV1FABP7FABP5CRBN | |
| SCHEMBL397661 | 0.75 | MEN1 (0.63) | KIF11NPC1CASP3RAB9ASENP7 | |
| SCHEMBL22424922 | 0.74 | RAB9A (0.59) | KIF11NPC1CASP3RAB9ASENP7 | |
| SCHEMBL395800 | 0.73 | KIF11 (0.52) | KIF11FABP7FABP5CRBN | |
| SCHEMBL25566546 | 0.72 | TRPV1 (0.57) | KIF11TRPV1NPC1RAB9ACRBN | |
| SCHEMBL25566737 | 0.71 | MAPT (0.51) | NPC1RAB9ACRBN | |
| SCHEMBL3662896 | 0.71 | CRBN (0.52) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| EP-2102190-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008073480-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073480-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NTRK2, PDGFRB, PDGFRA | KIF11 1787/4885TRPV1 2110/4885FABP7 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.